Patient group input submissions: Selexipag (Uptravi) for pulmonary arterial hypertension (WHO class II and III)
Questionnaires were promoted via Canadian cardiovascular health agencies to patients with pulmonary arterial hypertension to gather input on the effectiveness of selexipag in the treatment of the disease
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, 2017 Sep
|
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Questionnaires were promoted via Canadian cardiovascular health agencies to patients with pulmonary arterial hypertension to gather input on the effectiveness of selexipag in the treatment of the disease |
|---|---|
| Physical Description: | 1 PDF file (9 pages) illustrations |